Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 73 |
| Active Pipeline (Recruiting Now) | 46 (33) |
| Completed vs Stopped Early | 2 / 1 (1.4%) |
| Median Closed Actual Enrollment | 65 participants |
| Physical Hospital Site Disclosure | 100.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| The First Affiliated Hospital, Zhejiang University School of Medicine | Hangzhou, Zhejiang | 28 |
| The First Affiliated Hospital of Anhui Medical University | Hefei, Anhui | 5 |
| Zhongshan Hospital Fudan University | Shanghai | 4 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT07396480 | Fludarabine Plus Melphalan Versus Addition of Venetoclax to Fludarabine/Melphalan Conditioning Regimen for Allogeneic Hematopoietic Stem Cel | Phase III | RECRUITING |
| NCT07707687 | Safety and Efficacy of Eculizumab in High-risk TA-TMA | Phase II | RECRUITING |
| NCT07692841 | Single-Dose vs. Divided-Dose G-CSF for Stem Cell Mobilization in Healthy Allogeneic Donors | Phase III | RECRUITING |
| NCT06611813 | Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer (NEOTORCH-BREAST01) | Phase II | RECRUITING |
| NCT06977893 | Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer : a Randomized, Open-label, Parallel-controlled, Multi- | Phase III | RECRUITING |
Explore interactive annual charts and M&A subsidiary rollups in the First Affiliated Hospital of Zhejiang University Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.